New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Marvell Technology soars 363% on booming AI data center demand, but premium valuation and intense competition raise the question of whether to buy, sell or hold the stock.
Increasing power demands stemming from the data center buildout have led to record-breaking quarterly results from Caterpillar, with shares benefiting in a big way.
Although the revenue and EPS for DocuSign (DOCU) give a sense of how its business performed in the quarter ended April 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Snowflake stock gains 16% in a year as AI products and customer growth accelerated, but margin pressure, competition and a premium valuation cloud the outlook.
The 2026 Q2 earnings season will take the spotlight when the big banks report their results in mid-July. But we will already have seen fiscal May-quarter results from almost two dozen companies by then. What can investors expect?
APAs Permian cost cuts, debt reduction efforts and the GranMorgu project in Suriname (first oil expected in mid-2028) give it an edge over fellow oil and gas explorer Ovintiv.
Four drone-technology stocks, including ESLT, ADI, HEI and TDY, offer exposure to defense, AI and aerospace trends that could lift portfolio returns in 2026.
SIG says Grow Brand Love is gaining traction: Q1 comps up 1.8%, units improving and fiscal 2027 outlook raised to $6.7???$6.9B sales despite higher gold costs.
Energy Fuels trades at a steep premium to peers despite rising uranium output, REE expansion and a strong long-term outlook, but near-term losses persist.
The significant expansion of ROIC for both Computer-Office Equipment and Electronics from 2020 to today is a classic case of structural tech tailwinds.
ZUMZ shares sink after Q1 results, as a wider loss and a cautious Q2 outlook overshadow y/y sales growth, margin gains and another quarter of positive comps.
Accenture (ACN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LULU beats on Q1 EPS and revenues. But shares fall after hours as tariffs and markdowns squeeze margins and the company cuts FY26 view, as Americas comps slide.
Republic Services gains from rising waste volumes, AI-driven pricing and routing tools and active acquisitions, while industry competition remains a concern.
PetMed says FY26 reset is working. Its Q4 sales top estimates, margins improve, and it stays independent after $4-$4.25 offers and touts B2B expansion.